To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: * To evaluate the other safety aspects of sarilumab administered as monotherapy. * To assess the exposure of sarilumab administered as monotherapy.
Epistemonikos ID: 652b6d8fec8ee31dd49687e3ee5f5aab5febca90
First added on: Mar 23, 2022